| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ling-Yu Zhang, Qian-Qian Jin, Christian Hölscher, Lin L. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. Neural regeneration research. vol 16. issue 8. 2021-08-12. PMID:33433498. |
incretin hormones, including glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), can re-sensitize insulin signaling. |
2021-08-12 |
2023-08-13 |
rat |
| Tapan Behl, Aayush Sehgal, Madhuri Grover, Sukhbir Singh, Neelam Sharma, Saurabh Bhatia, Ahmed Al-Harrasi, Lotfi Aleya, Simona Bunga. Uncurtaining the pivotal role of ABC transporters in diabetes mellitus. Environmental science and pollution research international. vol 28. issue 31. 2021-08-12. PMID:34085197. |
in addition, the involvement of other pathways, including igf signaling, p13-akt/pkc/mapk signaling, and glp-1 via regulation of abct, may help develop new treatment strategies to cope with insulin resistance dysregulated glucose metabolism, key features in dm. |
2021-08-12 |
2023-08-13 |
Not clear |
| Gianluca Bianchini, Cecilia Nigro, Anna Sirico, Rubina Novelli, Immacolata Prevenzano, Claudia Miele, Francesco Beguinot, Andrea Aramin. A new synthetic dual agonist of GPR120/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 139. 2021-08-11. PMID:33895521. |
g-protein coupled receptors 40 and 120 (gpr40 and gpr120) are increasingly emerging as potential therapeutic targets for the treatment of altered glucose homeostasis, and their agonists are under evaluation for their glucagon-like peptide-1 (glp-1)-mediated therapeutic effects on insulin production and sensitivity. |
2021-08-11 |
2023-08-13 |
mouse |
| Xi Chen, Yongping Xu, Jianhua Zhang, Shiyin Shao, Yanran Duan, Peiwen Liu, Liya Shen, Jing Zhang, Jiaoe Zeng, Mei Lin, Shi Zhao, Jianhua Ma, Tao Zhao, Juping Hu, Yong Liao, Xiaowen Chen, Shufang Hu, Yaoming Xue, Zhaoyang Zeng, Wentao He, Zhelong Liu, Wenjun Li, Liegang Liu, Ping Yin, Xuefeng Y. Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 27. issue 8. 2021-08-10. PMID:33831552. |
switching to combination use of glp-1 agonist and basal insulin may be an alternative option. |
2021-08-10 |
2023-08-13 |
human |
| Jan Aaseth, Stian Ellefsen, Urban Alehagen, Tine M Sundfør, Jan Alexande. Diets and drugs for weight loss and health in obesity - An update. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 140. 2021-08-10. PMID:34082399. |
as for pharmacological aids, obese patients with type 2 diabetes or insulin resistance seem to benefit from lc diet combined with a glp-1 agonist, e.g. |
2021-08-10 |
2023-08-13 |
Not clear |
| Tohru Hira, Jukkrapong Pinyo, Hiroshi Har. What Is GLP-1 Really Doing in Obesity? Trends in endocrinology and metabolism: TEM. vol 31. issue 2. 2021-08-03. PMID:31636017. |
glucagon-like peptide-1 (glp-1) is a gastrointestinal hormone released in response to meal ingestion and enhances insulin secretion from pancreatic β cells. |
2021-08-03 |
2023-08-13 |
human |
| Arslan Chaudhry, Christopher Biggiani, Muhammad Afzal, Sohail Chaudhry, Yazan Vwic. Acute Pancreatitis-Induced Euglycemic Diabetic Ketoacidosis. Cureus. vol 13. issue 6. 2021-08-03. PMID:34336446. |
glucagon-like peptide-1 receptor agonists (glp-1 ras) are a class of medications utilized for the treatment of diabetes mellitus by mechanisms promoting incretin release and insulin production. |
2021-08-03 |
2023-08-13 |
Not clear |
| Zhi-Yang Zeng, Jia-Wei Lu, Xi-Ya Cao, Xin-Yue Wang, Da-Li L. A method for constructing GLP-1 overexpression intestinal organoids. Yi chuan = Hereditas. vol 43. issue 7. 2021-07-22. PMID:34284984. |
as a potent insulinotrophic hormone, glucagon-like peptide 1 (glp-1) is mainly secreted by intestinal l cells, which can effectively promote the release of insulin and thus reduce blood glucose. |
2021-07-22 |
2023-08-13 |
mouse |
| Michał Lis, Bartłomiej Stańczykiewicz, Paweł Liśkiewicz, Błażej Misia. Impaired hormonal regulation of appetite in schizophrenia: A narrative review dissecting intrinsic mechanisms and the effects of antipsychotics. Psychoneuroendocrinology. vol 119. 2021-07-21. PMID:32534330. |
early hormonal alterations that might be associated with intrinsic mechanisms include low levels of leptin and glucagon-like peptide-1 (glp-1) together with elevated insulin levels in first-episode psychosis (fep) patients. |
2021-07-21 |
2023-08-13 |
Not clear |
| Prawej Ansari, Mary P Hannon-Fletcher, Peter R Flatt, Yasser H A Abdel-Waha. Effects of 22 traditional anti-diabetic medicinal plants on DPP-IV enzyme activity and glucose homeostasis in high-fat fed obese diabetic rats. Bioscience reports. vol 41. issue 1. 2021-07-21. PMID:33416077. |
a.latifolia, a. marmelos, t. foenum-graecum and m. indica extracts improved glucose tolerance, insulin release, reduced dpp-iv activity and increased circulating active glp-1 in hff obese-diabetic rats (p<0.05-0.001). |
2021-07-21 |
2023-08-13 |
rat |
| Daniela Jakubowicz, Julio Wainstein, Shani Tsameret, Zohar Landa. Role of High Energy Breakfast "Big Breakfast Diet" in Clock Gene Regulation of Postprandial Hyperglycemia and Weight Loss in Type 2 Diabetes. Nutrients. vol 13. issue 5. 2021-07-20. PMID:34063109. |
most of the metabolic processes involved in pphg, i.e., β-cell secretory function, glp-1 secretion, insulin sensitivity, muscular glucose uptake, and hepatic glucose production, are controlled by the circadian clock and display daily oscillation. |
2021-07-20 |
2023-08-13 |
Not clear |
| Ameng Shi, Ting Li, Ying Zheng, Yahua Song, Haitao Wang, Na Wang, Lei Dong, Haitao Sh. Chlorogenic Acid Improves NAFLD by Regulating gut Microbiota and GLP-1. Frontiers in pharmacology. vol 12. 2021-07-20. PMID:34276380. |
serum transaminase, fasting blood glucose (fbg), blood lipids, insulin, glp-1 and lipopolysaccharide (lps) were detected. |
2021-07-20 |
2023-08-13 |
mouse |
| Nicola Marrano, Giuseppina Biondi, Anna Borrelli, Angelo Cignarelli, Sebastio Perrini, Luigi Laviola, Francesco Giorgino, Annalisa Natalicchi. Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity. Biomolecules. vol 11. issue 2. 2021-07-19. PMID:33671882. |
similar to glp-1, irisin augments insulin biosynthesis and promotes accrual of β-cell functional mass. |
2021-07-19 |
2023-08-13 |
Not clear |
| Matthew C Riddl. The current schemes of insulin therapy: Pro and contra. Diabetes research and clinical practice. vol 175. 2021-07-15. PMID:33865916. |
further changes in the structure or formulation of insulin are of uncertain potential, but schemes including delivery of amylin, glp-1, and glucagon show promise. |
2021-07-15 |
2023-08-13 |
Not clear |
| Habib Yaribeygi, Farin Rashid Farrokhi, Mohammed Altigani Abdalla, Thozhukat Sathyapalan, Maciej Banach, Tannaz Jamialahmadi, Amirhossein Sahebka. The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes. Journal of diabetes research. vol 2021. 2021-07-15. PMID:34258291. |
dpp-4 inhibitors are the other type of novel antidiabetic medications which act by preventing glp-1 inactivation and thereby increasing the activity levels of glp-1, leading to more glucose-induced insulin release from islet |
2021-07-15 |
2023-08-13 |
Not clear |
| Rory J McCrimmon, Saud Al Sifri, Rifat Emral, Viswanathan Mohan, Leobardo Sauque-Reyna, Carlos Trescolí, Nebojsa Lalic, Agustina Alvarez, Nacima Demil, Mathieu Coudert, Alka Shaunik, Mireille Bonnemaire, Julio Rosenstoc. Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial. Diabetes, obesity & metabolism. vol 23. issue 6. 2021-07-09. PMID:33606908. |
iglarlixi is a once-daily titratable fixed-ratio formulation that combines basal insulin glargine 100 units/ml (iglar) and the glp-1 ra, lixisenatide, which offers a single-injection option for treatment intensification, with improved hba1c reductions, similar hypoglycaemia risk and more favourable bodyweight profiles over iglar alone. |
2021-07-09 |
2023-08-13 |
Not clear |
| Ellen M Davis, Darleen A Sandova. Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function. Comprehensive Physiology. vol 10. issue 2. 2021-07-08. PMID:32163198. |
glp-1 activates glp-1 receptors (glp-1r) on the β-cell to induce insulin secretion in a glucose-dependent manner. |
2021-07-08 |
2023-08-13 |
Not clear |
| Ellen M Davis, Darleen A Sandova. Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function. Comprehensive Physiology. vol 10. issue 2. 2021-07-08. PMID:32163198. |
recent work suggests the possibility that this source of glp-1 is also be important in regulating nutrient-induced insulin secretion in a paracrine fashion. |
2021-07-08 |
2023-08-13 |
Not clear |
| Chelsea K Longwell, Stephanie Hanna, Nina Hartrampf, R Andres Parra Sperberg, Po-Ssu Huang, Bradley L Pentelute, Jennifer R Cochra. Identification of N-Terminally Diversified GLP-1R Agonists Using Saturation Mutagenesis and Chemical Design. ACS chemical biology. vol 16. issue 1. 2021-07-07. PMID:33307682. |
the glucagon-like peptide 1 receptor (glp-1r) is a class b g-protein coupled receptor (gpcr) and diabetes drug target expressed mainly in pancreatic β-cells that, when activated by its agonist glucagon-like peptide 1 (glp-1) after a meal, stimulates insulin secretion and β-cell survival and proliferation. |
2021-07-07 |
2023-08-13 |
Not clear |
| Kristoffer Niss, Magnus E Jakobsson, David Westergaard, Kirstine G Belling, Jesper V Olsen, Søren Bruna. Effects of active farnesoid X receptor on GLUTag enteroendocrine L cells. Molecular and cellular endocrinology. vol 517. 2021-07-05. PMID:32702472. |
this, in turn, reduces insulin secretion, which is triggered when β cells bind glp-1. |
2021-07-05 |
2023-08-13 |
Not clear |